 |
|
Home | Myriad Genetics’s “Neutral” Rating Reiterated at Zacks (MYGN) |
 |
Myriad Genetics’s “Neutral” Rating Reiterated at Zacks (MYGN)
|
 |
- September 26, 2014
-
Myriad Genetics (NASDAQ:MYGN)‘s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Thursday. They currently have a $40.00 target price on the stock. Zacks‘s price target points to a potential upside of 4.19% from the company’s current price. Zacks’ analyst wrote, “Myriad reported a mixed fourth-quarter fiscal 2014, with […]This article (Myriad Genetics’s “Neutral” Rating Reiterated at Zacks (MYGN)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2014/09/25/myriad-geneticss-neutral-rating-reiterated-at-zacks-mygn/
|
 |
|
 |
|
 |
